NCT02000193 - Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

December 31, 2018

Conditions

Breast Cancer

Interventions

DRUG

fulvestrant

"Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, and 29， then every 28 days.~The treatment will continue until disease progression or intolerable AE."

Trial Locations (1)

510060

State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou